Mexiletine

Mexiletine

SCHEMBL16081

Cc1cccc(C)c1OCC(C)N

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9A

The experimentally established mechanism targets of Mexiletine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SCN4A known ✓ P35499 12/20 1.00
▸ SCN5A known ✓ Q14524 3/20 1.00
▸ SCN1A known ✓ P35498 2/20 1.00
▸ SCN9A known ✓ Q15858 2/20 1.00
▸ SCN7A known ✓ Q01118 1/20 1.00
▸ SCN2A known ✓ Q99250 1/20 1.00
▸ SCN3A known ✓ Q9NY46 1/20 1.00
▸ SCN11A known ✓ Q9UI33 1/20 1.00
▸ SCN8A known ✓ Q9UQD0 1/20 1.00
▸ SCN10A known ✓ Q9Y5Y9 1/20 1.00
▸ LMNA P02545 3/20 1.00
▸ CYP2D6 P10635 3/20 1.00
▸ CYP1A2 P05177 2/20 1.00
▸ CYP3A4 P08684 2/20 1.00
▸ NFKB1 P19838 2/20 1.00
▸ TSHR P16473 2/20 1.00
▸ MAOA P21397 2/20 1.00
▸ CYP2C9 P11712 1/20 1.00
▸ KCNK3 O14649 1/20 1.00
▸ CACNA1F O60840 1/20 1.00

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
(R)-Mexiletine SCHEMBL16082 1.00 SCN4A (1.00) SCN4ASCN5ALMNACYP2D6SCN1A
(S)-Mexiletine SCHEMBL13046569 1.00 SCN4A (1.00) SCN4ASCN5ALMNACYP2D6SCN1A
Mexiletine SCHEMBL8858385 1.00 SCN4A (1.00) SCN4ASCN5ALMNACYP2D6SCN1A
(R)-Mexiletine SCHEMBL29366590 0.98 SCN5A (1.00) SCN4ASCN5ALMNACYP2D6SCN1A
Mexiletine SCHEMBL6665250 0.98 SCN5A (1.00) SCN4ASCN5ALMNACYP2D6SCN1A
Mexiletine SCHEMBL6521444 0.98 SCN5A (1.00) SCN4ASCN5ALMNACYP2D6SCN1A
Mexiletine SCHEMBL42226 0.98 SCN5A (1.00) SCN4ASCN5ALMNACYP2D6SCN1A
(S)-Mexiletine SCHEMBL3645798 0.98 SCN5A (1.00) SCN4ASCN5ALMNACYP2D6SCN1A
Mexiletine SCHEMBL1652207 0.96 SCN4A (0.92) SCN4ASCN5ALMNACYP2D6SCN1A
Mexiletine SCHEMBL6518643 0.89 SCN4A (0.80) SCN4ASCN5ALMNACYP2D6SCN1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Appears in 16608 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-122094963-A Cardioprotective lipids and methods of use — 2026-05-26 — — CN claimed
US-20260097012-A1 COMPOSITIONS AND METHODS FOR TREATING GRAFT-RELATED ARRHYTHMIA BLUEROCK THERAPEUTICS LP (US) 2026-04-09 — — US claimed
US-12565653-B2 ATAXIN3 (ATXN3) RNAi agent compositions and methods of use thereof ALNYLAM PHARMACEUTICALS, INC. (US) 2026-03-03 — — US claimed
EP-4683627-A1 AMELIORATION OF DRUG-DRUG INTERACTIONS Ontrack Therapeutics Limited (GB) 2026-01-28 — — EP claimed
EP-4680201-A1 COMPOSITIONS AND USES THEREOF FOR STABILIZATION OF BLOOD SAMPLE COMPONENTS Streck LLC (US) 2026-01-21 — — EP claimed
US-12528794-B2 MAO-B inhibitor DRG-MAOB-1 for use in treatment of neurodegenerative diseases BAHCESEHIR UNIVERSITESI (TR) 2026-01-20 — — US claimed
WO-2025230475-A1 BETA-SILYL ALKYNOATES: VERSATILE REAGENTS FOR BIOCOMPATIBLE AND SELECTIVE AMIDE BOND FORMATION NANYANG TECHNOLOGICAL UNIVERSITY (SG) 2025-11-06 — — WO claimed
EP-4593821-A2 COMPOSITIONS AND METHODS FOR TREATING GRAFT-RELATED ARRHYTHMIA Bluerock Therapeutics LP (US) 2025-08-06 — — EP claimed
EP-4587119-A1 METHODS OF TREATMENT WITH AN IBOGA ALKALOID The Board of Trustees of the Leland Stanford Junior University (US) 2025-07-23 — — EP claimed
EP-4587019-A2 COMPOSITIONS OF IBOGA ALKALOIDS AND METHODS OF TREATMENT The Board of Trustees of the Leland Stanford Junior University (US) 2025-07-23 — — EP claimed
US-5585243-A SEPARATELY INCUBATING HUMAN PLATELETS WITH BLOOD SAMPLE ANDREAGENT DRUG SOLUTION TO FORM COMPLEXES, DETERMINING AMOUNT OF BOUND ANTIBODY THE BLOOD CENTER OF SOUTHEASTERN WISCONSIN, INC. (US) 1996-12-17 — — US claimed
EP-0659082-A1 USE OF CYTOCHROME P450 INHIBITORS FOR INHIBITING THE METABOLISM OF NITROGEN SUBSTITUTED ACRIDINE WARNER-LAMBERT COMPANY (US) 1995-06-28 — — EP claimed
WO-1995008116-A1 METHOD OF DETECTING CYTOPENIA THAT IS MEDIATED BY DRUG-DEPENDENT ANTIBODY BINDING TO BLOOD CELLS THE BLOOD CENTER OF SOUTHEASTERN WISCONSIN, INC. (US) 1995-03-23 — — WO claimed
WO-1994005296-A2 USE OF CYTOCHROME P450 INHIBITORS FOR INHIBITING THE METABOLISM OF NITROGEN SUBSTITUTED ACRIDINE WARNER-LAMBERT COMPANY (US) 1994-03-17 — — WO claimed
EP-0406289-A1 PREPARATION FOR PROMOTING AND STIMULATING HAIR GROWTH BOEHRINGER INGELHEIM INTERNATIONAL GmbH (DE) 1991-01-09 — — EP claimed
WO-1989009046-A1 PREPARATION FOR PROMOTING AND STIMULATING HAIR GROWTH BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 1989-10-05 — — WO claimed
US-4557934-A ALONG WITH A DIOL PYRROLIDONE OR AN AZACYCLOPENTAN-2-ONE THE PROCTER & GAMBLE COMPANY (US) 1985-12-10 — — US claimed
US-4459279-A MEXILETINE, WATER INSOLUBLE FILM FORMER, SUSTAINED RELEASE BOEHRINGER INGELHEIM GMBH (DE) 1984-07-10 — — US claimed
US-4031244-A ANTICONVULSIVES, ANTIARRHYTHMIA BOEHRINGER INGELHEIM GMBH (DT) 1977-06-21 — — US claimed
US-3954872-A 1-(2',6'-Dimethyl-phenoxy)-2-amino-alkanes and salts thereof BOEHRINGER INGELHEIM GMBH (DT) 1976-05-04 — — US claimed
Send feedback